outcome

Immunological markers of optimal response to natalizumab in multiple sclerosis.

Villar LM, García-Sánchez MI, Costa-Frossard L, Espiño M, Roldán E, Páramo D, et al.. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol. 2012;69(2):191-7. doi: 10.1001/archneurol.2011.971. PubMed PMID: 22332187.

Stiff-man syndrome and variants: clinical course, treatments, and outcomes.

McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog EJ, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69(2):230-8. doi: 10.1001/archneurol.2011.991. PubMed PMID: 22332190.

Failure of natalizumab to prevent relapses in neuromyelitis optica.

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung H-P, et al.. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69(2):239-45. doi: 10.1001/archneurol.2011.216. PubMed PMID: 22332191.

Mediterranean diet and white matter hyperintensity volume in the Northern Manhattan Study.

Gardener H, Scarmeas N, Gu Y, Boden-Albala B, Elkind MSV, Sacco RL, et al. Mediterranean diet and white matter hyperintensity volume in the Northern Manhattan Study. Archives of Neurology. 2012;69(2):251-6. DOI: 10.1001/archneurol.2011.548. PubMed PMID: 22332193; PubMed Central PMCID: PMC3281550.